Abstract OBJECTIVE: To study the effect of risperidone treatment on behavioral disorders in children with autism. METHODS: Forty children with behavioral disorders (aged from 5 to 12 years) were treated with risperidone for 8 weeks. The behavioral symptoms were evaluated by the Clinical Global Impression (CGI) and the Autism Treatment Evaluation Checklist (ATEC) before and after the treatment. The adverse events related to risperidone treatment were observed. RESULTS: The score of severity of illness and the ATEC total scores were significantly reduced 8 weeks after risperidone treatment. Besides the social intercourse ability, great improvements have been shown on the verbal communication, apperception and behavioural symptoms by the ATEC. No severe adverse events related to risperidone treatment were observed. CONCLUSIONS: Risperidone can significantly improve the behavioral disorders in children with autism and is well-tolerated.
WEI Bin-Yuan,HUANG Fei,QIN Xiao-Tian et al. Treatment of behavioral disorders by risperidone in children with autism[J]. 中国当代儿科杂志, 2011, 13(3): 216-218.
WEI Bin-Yuan,HUANG Fei,QIN Xiao-Tian et al. Treatment of behavioral disorders by risperidone in children with autism[J]. CJCP, 2011, 13(3): 216-218.
［1］Liu T, Dhanasekaran SM, Jin H, Hu B, Tomlins SA, Chinnaiyan AM, et al. FIZZ1 stimulation of myofibroblast differentiation［J］. Am J Pathol, 2004, 164(4): 1315-1326.
［2］Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, et al. FIZZl, a novel cysteinerich secreted protein associated With pulmonary inflammation, defines a new gene family［J］. EMBO J, 2000, 19(15): 4046-4055.
［3］Axelson H. Notch signaling and cancer: emerging complexity［J］. Semin Cancer Biol, 2004, 14(5): 317-319.
［4］Katsuma S, Nishi K, Tanigawara K, Ikawa H, Shiojima S, Takagaki K, et al. Molecular monitoring of bleomycin-induced pulmonary fibrosis by cDNA microarray-based gene expression profiling［J］. Biochem Biophys Res Commun, 2001, 288(4): 747751.
［5］Liu T, Hu B, Choi YY, Chung M, Ullenbruch M, Yu H, et al. Notch1 signaling in FIZZ1 induction of myofibroblast differentiation［J］. Am J Pathol, 2009,174(5):1745-1755.
［6］Patel L, Buckels AC, Kinghom IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by gamma activators［J］. Biochem Biophys Res Commu, 2003, 300(2):472-476.
［8］An SS, Bai TR, Bates JH, Black JL, BrownRH, Brusasco V, et al. Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma［J］. Eur Respir J, 2007, 29(5): 834-860.
［9］Vignola AM , Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V, et al. Airway remodeling in asthma［J］. Chest, 2003, 123(3 Suppl):417S-422S.
［10］Gerstmayer B, Küsters D, Gebel S, Müller T, Van Miert E, Hofmann K, et al. Identification of RELMgamma, a novel resistin-like molecule with a distinct expression pattern［J］．Genomics, 2003, 81(6): 588-595.
［11］Sweeney C, Morrow D, Birney YA, Coyle S, Hennessy C, Scheller A, et al. Notch 1 and 3 receptor signaling modulates vascular smooth muscle cell growth, apoptosis, and migration via a CBF-1/RBP-Jk dependent pathway［J］. FASEB J, 2004, 18(12): 1421-1423.
［12］Havrda MC, Johnson MJ, O′Neill CF, Liaw L. A novel mechanism of transcriptional repression of p27kip1 through Notch/HRT2 signaling in vascular smooth muscle cells［J］. Thromb Haemost, 2006, 96(3):361-370.
［13］Wang W, Prince CZ, Hu X, Pollman MJ. HRT1 modulates vascular smooth muscle cell proliferation and apoptosis［J］. Biochem Biophys Res Commun, 2003, 308(3): 596-601.
［14］Doi H, Iso T, Sato H, Yamazaki M, Matsui H, Tanaka T, et al. Jagged1-selective notch signaling induces smooth muscle differentiation via a RBP-Jkappa-dependent pathway［J］. J Biol Chem, 2006, 281(39): 28555-28564.
［15］Noseda M, Fu Y, Niessen K, Wong F, Chang L, McLean G, et al. Smooth muscle alpha-actin is a direct target of Notch/CSL［J］. Circ Res, 2006, 98(12):1468-1470.
